SCM
PRDS

Soleus Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Soleus Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,250,000
Closed -$1.65M – 113
2023
Q1 		$1.65M Hold
1,250,000
– – 0.17% 67
2022
Q4 		$2.11M Buy
+1,250,000
New +$1.58M 0.3% 57

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

Soleus Capital Management's PRDS Position: Q2 2023 in Review

Soleus Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 1,250,000 shares — an estimated $1.65M sold.

Soleus Capital Management first reported a position in PRDS in Q4 2022 and held it in 2 quarters. The position peaked at $2.11M in Q4 2022. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

  • Soleus Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Soleus Capital Management sold 1,250,000 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.65M.
  • Soleus Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Soleus Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $2.11M in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.